The Lung Drug That Doesn't Just Slow the Damage. It Might Undo It.

Let that sink in. In a disease where "slowing the decline" has been the ceiling of ambition for years, this drug appeared to push the needle backwards. FierceBiotech framed taladegib as potentially the first drug to reduce lung fibrosis while increasing total lung capacity.

There was also a numerical improvement on a quality-of-life questionnaire (the Living with Pulmonary Fibrosis survey), though that measure wasn't powered for statistical significance. On the safety front, serious adverse event rates were balanced between the drug and placebo groups, which is exactly what you want to see.

The Hedgehog in the Room

So how does taladegib work? The answer involves a signaling pathway with one of biology's most delightful names: the Hedgehog pathway.

The Hedgehog (Hh) pathway is critical during embryonic development. It helps cells figure out where to go and what to become. In healthy adults, it's mostly quiet, like a construction crew that finishes the house and goes home.

But in IPF, the Hedgehog pathway gets switched back on. Injured lung cells start pumping out a signal called SHH, which tells nearby cells to transform into myofibroblasts: the cellular equivalent of rogue contractors who keep pouring concrete long after the renovation is done. These myofibroblasts produce excess scar tissue, resist normal cell death, and create a self-reinforcing loop with another major fibrosis driver called TGF-β.

Taladegib works by blocking a receptor called Smoothened (SMO) on the Hedgehog pathway, essentially cutting the phone line between the injured cells and the rogue contractors. Without the signal, the hope is that the fibrotic maintenance program breaks down and the body can start cleaning up the mess.

It's an elegant idea, but there's a caveat worth mentioning. Some animal studies have shown that blocking Hedgehog signaling didn't prevent fibrosis in certain models, suggesting that timing and disease stage matter a lot. The fact that Endeavor is seeing positive signals in human patients, though, is a genuinely encouraging sign that they may have gotten the biology right.

Why IPF Is Such a Brutal Market (and Opportunity)

IPF is one of those diseases that makes even seasoned pulmonologists feel helpless. Median survival after diagnosis ranges from two to five years. The scarring is progressive, irreversible (until maybe now), and there's no cure short of a lung transplant, which only a small fraction of patients can receive.

The two drugs that have defined IPF treatment for years are pirfenidone and nintedanib. Both are oral antifibrotics that slow the rate of lung function decline. They don't stop it. They definitely don't reverse it. And they come with side effects that many patients struggle to tolerate.

In 2025, a third approved drug joined the mix: nerandomilast (brand name Jascayd), from Boehringer Ingelheim. But the fundamental limitation remains the same. Every approved IPF therapy is playing defense, trying to slow the clock rather than turn it back.

That's why Endeavor's data, if it holds up in larger trials, could be genuinely paradigm-shifting. We're not talking about a marginal improvement. We're talking about a potential category change from "disease management" to "disease reversal."

A Crowded Pipeline, but Few Like This

Endeavor isn't the only company chasing better IPF treatments. The pipeline is packed. One 2026 landscape analysis counted 150 unique IPF programs in development, with 98 of them being small molecules. Over 80 companies are in the hunt.

The biggest names in the late-stage race include Bristol Myers Squibb (with BMS-986278, an LPA1 antagonist in Phase 3), Pliant Therapeutics (bexotegrast, an integrin inhibitor in Phase 2/3), and Celea Therapeutics (deupirfenidone, a next-gen pirfenidone designed for better tolerability). GSK, Mediar Therapeutics, and even AI-drug-discovery darling Insilico Medicine all have late-stage or mid-stage IPF programs running.

But almost every one of these competitors is still working within the "slow the decline" framework. Different targets, different mechanisms, same fundamental goal: reduce the rate of lung function loss.

Endeavor's Hedgehog approach occupies a distinct lane. If taladegib truly reverses fibrosis rather than just putting the brakes on it, the competitive dynamics shift dramatically. It's the difference between selling a better umbrella and selling a machine that stops the rain.

What We Don't Know Yet

Before anyone gets too excited, some important caveats. Endeavor has released topline data, not the full dataset. We don't yet have exact effect sizes, p-values, dose-response curves, or subgroup breakdowns. The company said detailed results will be presented at a future medical meeting, which means the data will face serious scrutiny from independent experts before the picture is complete.

Twenty-four weeks is also a relatively short window for a chronic, progressive disease. The key question going forward: does the improvement last? Does it compound? Or does it plateau? A Phase 3 trial over 52 weeks or longer will be essential to answer those questions.

And then there's the broader biological question. The Hedgehog pathway's role in fibrosis is context-dependent. What works at one stage of disease may not work at another. Endeavor has clearly found something promising in this patient population, but the translation from Phase 2b to Phase 3 has humbled many a biotech before.

The Bottom Line

Endeavor BioMedicines is a clinical-stage company, founded in 2018 by John Hood and Miguel de los Rios, that has been quietly building toward this moment. Their bet on the Hedgehog pathway was always a bit unconventional. Most of the IPF world was focused on other mechanisms. But unconventional bets are what move medicine forward.

If these Phase 2b results hold up in confirmatory trials, taladegib could become the first IPF drug that doesn't just manage the disease but actually fights back against it. For the roughly three million people worldwide living with IPF, that's not incremental progress. That's a different conversation entirely.

The full data presentation is still to come, and the road to approval is long. But for the first time in a long time, the IPF story has a new word in it: reversal.

And that word changes everything.

Roche Is Hiring a Chinese Startup to Invent Its Next Cancer Drug

Roche signed a deal worth up to $1 billion with Defand Therapeutics, a two-year-old Chinese startup with zero clinical trials, to discover molecular glue cancer drugs. It's Roche's fourth China partnership since August, and it signals a radical shift in how big pharma thinks about drug discovery.